+1 (304) 470-2225

Marker Therapeutics speaks on MultiTAA, therapy for Pancreatic Adenocarcinoma, the silent killer

The 56th session of the American Society of Clinical Oncology (ASCO) was forced virtually this year due to the COVID19. The ASCO20 Virtual Scientific Program meeting was rounded up with almost 250 virtual oral abstract presentations and virtual 2,500 poster presentations in 24 disease-based and specialty tracks. We Mellalta meets were able to collect the insights and point out one area which stands out.

ASCO Virtual Science Program 2020 involved global giants of pharmaceuticals with their prime focus in Oncology. Janssen highlighted its oncology portfolio while Merck & Pfizer demonstrated their potential of Bavencio in GTT, along with AstraZeneca showcasing its leadership in lung cancer across early- and late-stage disease and reinforce its biomarker-driven approach.

However, one new research that caught the eye was Marker Therapeutics announcing Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma.

Marker Therapeutics, Inc.

Pancreatic cancer is said to be the seventh leading cause of death, globally. Whereas it ranks third most leading cause of death in US. More than 53% of the patients get diagnosed late at the distant stage I.e. stage IV or the Metastatic, with survival rate of only 3%.

It’s a scary stat, as it gets un-noticed until late stages when the actual symptoms start to show up. Often termed as the silent killer.

The ongoing investigator-sponsored Phase 1 trial led by the Baylor College of Medicine for Marker therapeutics’ MultiTAA-specific T cell therapy’s data were reviewed at the 2020 ASCO virtual meeting.

Marker therapeutics in their Interim Results of its MultiTAA-Specific T Cell Therapy demonstrated potential of MultiTAA-specific T cell therapy in combination with chemotherapy as a first-line treatment option for patients with advanced or metastatic pancreatic adenocarcinoma in the early stage trial.

Study Title “A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multiantigen specific T cells in the first-line setting (TACTOPS)”

The study also showed the evidence of epitope-spreading in all responders, suggesting that MultiTAA-specific T cell therapy triggered the recruitment of a broader endogenous immune system response.

Dr. Brandon G. Smaglo, M.D, FACP, Department of Gastrointestinal Medical Oncology, said
“we also observed induction of the endogenous immune system – or epitope spreading – suggesting that the benefits of MultiTAA may extend beyond the targeted antigens and further contribute to a long-lasting anti-tumor effect.”

The therapy showed impressive results and demands further research.

Clinical trial information: NCT03192462

You might be interested in …

Leave a Reply

Get In Touch

Let's keep the conversation going